[go: up one dir, main page]

MX2018003411A - Terapia glucodirigida. - Google Patents

Terapia glucodirigida.

Info

Publication number
MX2018003411A
MX2018003411A MX2018003411A MX2018003411A MX2018003411A MX 2018003411 A MX2018003411 A MX 2018003411A MX 2018003411 A MX2018003411 A MX 2018003411A MX 2018003411 A MX2018003411 A MX 2018003411A MX 2018003411 A MX2018003411 A MX 2018003411A
Authority
MX
Mexico
Prior art keywords
compositions
liver
various embodiments
therapeutic
immunotolerance
Prior art date
Application number
MX2018003411A
Other languages
English (en)
Inventor
A Hubbell Jeffrey
Scott Wilson David
Original Assignee
Ecole Polytechnique Fed Lausanne Epfl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/859,292 external-priority patent/US10946079B2/en
Priority claimed from US15/185,564 external-priority patent/US10046056B2/en
Application filed by Ecole Polytechnique Fed Lausanne Epfl filed Critical Ecole Polytechnique Fed Lausanne Epfl
Publication of MX2018003411A publication Critical patent/MX2018003411A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2/00—Processes of polymerisation
    • C08F2/38—Polymerisation using regulators, e.g. chain terminating agents, e.g. telomerisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F2438/00—Living radical polymerisation
    • C08F2438/03—Use of a di- or tri-thiocarbonylthio compound, e.g. di- or tri-thioester, di- or tri-thiocarbamate, or a xanthate as chain transfer agent, e.g . Reversible Addition Fragmentation chain Transfer [RAFT] or Macromolecular Design via Interchange of Xanthates [MADIX]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)

Abstract

Varias modalidades de la presente divulgación se refieren a composiciones terapéuticas configuradas para dirigirse al hígado de un sujeto y que son útiles en el tratamiento o prevención de uno o más de los siguientes: rechazo de trasplante, enfermedad autoinmune, alergia alimentaria y respuesta inmune contra un agente terapéutico. En varias modalidades, las composiciones están configuradas para dirigirse al hígado y liberar antígenos para los que se desea la tolerancia. En varias modalidades, las composiciones están configuradas para la depuración de una proteína o péptido circulante o un anticuerpo asociado con una o más de los padecimientos mencionados anteriormente. Los métodos y usos de las composiciones para la inducción de la inmunotolerancia también se describen en la presente.
MX2018003411A 2015-09-19 2016-09-16 Terapia glucodirigida. MX2018003411A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/859,292 US10946079B2 (en) 2014-02-21 2015-09-19 Glycotargeting therapeutics
US15/185,564 US10046056B2 (en) 2014-02-21 2016-06-17 Glycotargeting therapeutics
PCT/IB2016/001411 WO2017046652A1 (en) 2015-09-19 2016-09-16 Glycotargeting therapeutics

Publications (1)

Publication Number Publication Date
MX2018003411A true MX2018003411A (es) 2018-09-06

Family

ID=57121450

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018003411A MX2018003411A (es) 2015-09-19 2016-09-16 Terapia glucodirigida.

Country Status (12)

Country Link
EP (2) EP4385520A3 (es)
JP (3) JP7082045B2 (es)
KR (1) KR20180080195A (es)
CN (3) CN108430497B (es)
AU (1) AU2016325073B2 (es)
CA (1) CA2998066A1 (es)
EA (1) EA036102B9 (es)
HK (1) HK1257845A1 (es)
IL (3) IL306015B2 (es)
MX (1) MX2018003411A (es)
NZ (2) NZ780070A (es)
WO (1) WO2017046652A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807942C (en) 2010-08-10 2021-07-27 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
ES2874884T3 (es) 2014-02-21 2021-11-05 Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto Compuestos terapéuticos dirigidos a la glucosa
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
CN108430497B (zh) * 2015-09-19 2024-05-07 洛桑聚合联合学院 糖靶向治疗剂
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
WO2019069993A1 (en) 2017-10-03 2019-04-11 Chugai Seiyaku Kabushiki Kaisha ANTI-HLA-DQ2.5 ANTIBODIES
EP3790577A4 (en) 2018-05-09 2022-04-27 The University of Chicago COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE
CN111214461B (zh) * 2020-03-24 2021-04-16 河南大学 糖靶向修饰siRNA纳米粒子的制备及应用
CN116819072B (zh) * 2023-08-28 2023-11-17 迪亚莱博（张家港）生物科技有限公司 一种用于抗aqp4自身抗体检测的抗原蛋白组合物及化学发光检测试剂盒
WO2025210538A1 (en) * 2024-04-02 2025-10-09 Biohaven Therapeutics Ltd. Bifunctional degraders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008504531A (ja) * 2004-06-24 2008-02-14 ザ スクリップス リサーチ インスティテュート 切断可能なリンカーを有するアレイ
EP2523686A2 (en) * 2010-01-14 2012-11-21 Glaxo Group Limited Liver targeting domain antibodies
CA2807942C (en) 2010-08-10 2021-07-27 Ecole Polytechnique Federale De Lausanne Erythrocyte-binding therapeutics
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US8501930B2 (en) * 2010-12-17 2013-08-06 Arrowhead Madison Inc. Peptide-based in vivo siRNA delivery system
EP2717919B1 (en) * 2011-06-03 2016-08-03 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
CN110075283A (zh) * 2012-02-15 2019-08-02 洛桑聚合联合学院 红细胞结合性治疗剂
JP2015525792A (ja) * 2012-08-09 2015-09-07 ロシュ グリクアート アクチェンゲゼルシャフト Ａｓｇｐｒ抗体およびその使用
ES2874884T3 (es) * 2014-02-21 2021-11-05 Ecole Polytechnique Fed De Lausanne Epfl Epfl Tto Compuestos terapéuticos dirigidos a la glucosa
CN108430497B (zh) 2015-09-19 2024-05-07 洛桑聚合联合学院 糖靶向治疗剂

Also Published As

Publication number Publication date
CA2998066A1 (en) 2017-03-23
JP2022028673A (ja) 2022-02-16
IL257958B2 (en) 2024-02-01
CN108430497A (zh) 2018-08-21
CN118436774A (zh) 2024-08-06
JP7082045B2 (ja) 2022-06-07
IL306015A (en) 2023-11-01
JP2018532722A (ja) 2018-11-08
EA036102B9 (ru) 2020-12-30
EP3349784A1 (en) 2018-07-25
JP7434248B2 (ja) 2024-02-20
HK1257845A1 (zh) 2019-11-01
IL306015B1 (en) 2025-01-01
JP2024063005A (ja) 2024-05-10
IL306015B2 (en) 2025-05-01
NZ780070A (en) 2024-11-29
EP4385520A3 (en) 2024-09-11
CN108430497B (zh) 2024-05-07
EA201890778A1 (ru) 2018-08-31
AU2023203475A1 (en) 2023-06-29
WO2017046652A1 (en) 2017-03-23
AU2016325073B2 (en) 2023-03-16
KR20180080195A (ko) 2018-07-11
IL257958A (en) 2018-06-28
EP4385520A2 (en) 2024-06-19
AU2016325073A1 (en) 2018-04-05
NZ780072A (en) 2024-11-29
IL317262A (en) 2025-01-01
EA036102B1 (ru) 2020-09-29
BR112018005409A2 (pt) 2018-10-09
CN118576700A (zh) 2024-09-03
NZ740689A (en) 2024-11-29
IL257958B1 (en) 2023-10-01

Similar Documents

Publication Publication Date Title
MX2018003411A (es) Terapia glucodirigida.
NZ723879A (en) Glycotargeting therapeutics
MX2017007256A (es) Inhibidor de bromodominio como adyuvante en la inmunoterapia contra el cancer.
CL2017003023A1 (es) Anticuerpos anti-ctla-4 y métodos de uso de los mismos.
JOP20190055A1 (ar) أجسام مضادة ضد cd27
SV2018005678A (es) Anticuerpo que neutraliza el virus respiratorio sincitial humano
MX2018011216A (es) Moléculas pequeñas contra cereblon para mejorar la función efectora de los linfocitos t.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
BR112017008165A2 (pt) anticorpos de domínio único direcionados contra antígenos intracelulares
MX2019015311A (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
WO2015132675A3 (en) Methods and compositions for modifying the immune response
MX394103B (es) Anticuerpos anti-angptl8 y usos de estos.
MX385845B (es) Usos y composiciones de la flagelina
GT201700188A (es) Anticuerpos contra tau y sus usos
MX2020010194A (es) Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas.
CL2018001652A1 (es) Composiciones y métodos para disminuir la expresión de tau
MX2016012938A (es) Composiciones estables de yodo no en complejo y metodos de uso.
CL2018003284A1 (es) Métodos de tratamiento de enfermedades autoinmunes usando linfocitos t alogénicos.
MX2018003700A (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos.
MX2017008815A (es) Composicion que contiene quitina y proteinas digeribles.
MX389320B (es) Anticuerpos anti-tnfrsf25
BR112017007748A2 (pt) “composição farmacêutica, agente antialérgico, composição alimentar, composição cosmética, uso de um extrato, e, método para prevenir ou tratar uma doença alérgica
WO2015123493A3 (en) Compositions and methods for modulatuion of immune response